Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. BB Biotech AG
  6. News
  7. Summary
    BION   CH0038389992

BB BIOTECH AG

(BION)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.60 per share

03/18/2021 | 11:48am EST
DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM/Dividend 
Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.60 per share 
2021-03-18 / 17:45 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Media Release as of March 18, 2021 
Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.60 per share 
All proposals of BB Biotech AG's Board of Directors were approved by shareholders at its Annual General Meeting held 
today. In accordance with the COVID-19 Ordinance 2, the voting rights of shareholders were exclusively exercised 
through the independent proxy as per their instructions, since shareholders were not allowed to attend the meeting in 
person. 
Shareholders voted in favor of the proposal to pay out a dividend of CHF 3.60 per share. Payment will be made on March 
24, 2021, the record date is March 23, 2021 and the ex-dividend date is March 22, 2021. 
Shareholders elected the previous board members Dr. Erich Hunziker, Chairman, Dr. Clive Meanwell, Dr. Susan Galbraith, 
Prof. Dr. Mads Krogsgaard Thomsen and Dr. Thomas von Planta to another one-year term of office. 
 
Investor Relations 
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00 
Dr. Silvia Schanz, ssc@bellevue.ch 
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch 
Claude Mikkelsen, cmi@bellevue.ch 
Media Relations 
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00 
Tanja Chicherio, tch@bellevue.ch 
TE Communications AG, St. Leonhard-Strasse 45, 9001 St. Gallen, Switzerland, Tel. +41 79 423 22 28 
Thomas Egger, teg@te-communications.ch 
www.bbbiotech.com 
 
Company profile 
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in 
Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are 
mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech 
builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the 
experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions. 
Disclaimer 
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such 
statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject 
to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and 
its directors and officers accept no responsibility in that regard. All forward-looking statements included in this 
release are made only as of the date of this release and BB Biotech and its directors and officers undertake no 
obligation to update any forward-looking statements as a result of new information, future events or other factors. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-03-18 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      BB BIOTECH AG 
              Schwertstrasse 6 
              8200 Schaffhausen 
              Switzerland 
Phone:        +41 52 624 08 45 
E-mail:       info@bbbiotech.com 
Internet:     www.bbbiotech.ch 
ISIN:         CH0038389992 
WKN:          A0NFN3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Mailand, SIX 
EQS News ID:  1176751 
 
End of News   DGAP News Service 
=------------ 

1176751 2021-03-18

(END) Dow Jones Newswires

March 18, 2021 12:47 ET (16:47 GMT)

All news about BB BIOTECH AG
10/22BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
10/22BB BIOTECH : Q3 Net Loss Shrinks
MT
10/22BB BIOTECH : increases positions in oncology and CNS
PU
10/22BB BIOTECH : publishes its interim report
EQ
10/22BB BIOTECH : Gains realized following COVID-19 vaccine booster update enable increases in ..
EQ
07/23Bb Biotech Ag Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/23BB BIOTECH : Posts Lower H1 Profit, Operating Income
MT
07/23BB BIOTECH : Interim report as at June 30, 2021
PU
07/23BB BIOTECH : publishes its interim report
EQ
07/23BB BIOTECH : Solid second quarter for the biotech industry - BB Biotech raised its allocat..
EQ
More news
Analyst Recommendations on BB BIOTECH AG
More recommendations
Financials
Sales 2021 -175 M -191 M -191 M
Net income 2021 439 M 479 M 479 M
Net Debt 2021 23,5 M 25,5 M 25,5 M
P/E ratio 2021 7,39x
Yield 2021 5,35%
Capitalization 4 166 M 4 532 M 4 539 M
EV / Sales 2021 -23,9x
EV / Sales 2022 -
Nbr of Employees 10
Free-Float 98,1%
Chart BB BIOTECH AG
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 75,20 CHF
Average target price 97,00 CHF
Spread / Average Target 29,0%
EPS Revisions
Managers and Directors
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BB BIOTECH AG1.42%4 532
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298